ALVO Alvotech
Price Chart
Executive Summary
Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due to a production slowdown that impacted revenues and EBITDA. Management maintained 2026 revenue guidance of $650-700M and outlined progress on FDA resubmission and pipeline, but the weak quarterly results will likely pressure the stock near term.
Key Financial Metrics
Actionable Insight
Expect initial negative reaction to the deep EPS miss and revenue decline, but monitor for a potential recovery if the FDA resubmission progresses as planned in Q2. The maintained guidance suggests management sees the production issues as temporary, providing a possible floor.
Key Facts
- Q1 2026 revenue $105.9M vs $132.8M YoY (down 20.3%)
- GAAP EPS -$0.37 vs consensus $0.06 (miss of -716.7%)
- Adjusted EBITDA $24.4M with gross margin of 57%
- Management maintained 2026 revenue guidance of $650-700M and adjusted EBITDA guidance of $180-220M
- Production slowdown related to facility improvements impacted quarterly results
- FDA BLA resubmission planned for Q2 2026; pipeline advances including AVT16/AVT80 submissions and AVT29 pivotal study
- Entered into strategic manufacturing agreement with FUJIFILM Biotechnologies
Financial Impact
Revenue declined ~$27M YoY; EPS missed consensus by $0.43 per share
Risk Factors
- Further delays in FDA resubmission or rejection of BLAs
- Prolonged production disruptions impacting future revenue
- Competitive pressure in biosimilar markets
- Execution risk on pipeline milestones
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
7d ago
|
Press Release
| $3.55 awaiting T+1 | awaiting T+1 | — | $4.17 (+17.63%) |
|
Jun 8, 2026
7d ago
|
Press Release
| $3.55 awaiting T+1 | awaiting T+1 | — | $4.17 (+17.63%) |
|
Jun 4, 2026
11d ago
|
Press Release
| $3.74 $3.54 | ▼ −5.35% | ▼ −2.75% | $4.17 (+11.50%) |
|
May 11, 2026
5w ago
|
Press Release
| $3.59 $3.55 | ▼ −1.11% | ▼ −0.98% | $4.17 (+16.16%) |
|
May 11, 2026
5w ago
|
Press Release
| $3.59 $3.55 | ▼ −1.11% | ▼ −0.98% | $4.17 (+16.16%) |
|
May 6, 2026
5w ago
|
Press Release
| $3.20 $3.20 | · 0.00% | ▲ +0.83% | $4.17 (−30.31%) |
|
May 6, 2026
5w ago
|
Press Release
| $3.20 $3.20 | · 0.00% | ▲ +0.83% | $4.17 (−30.31%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $3.38 $3.30 | ▼ −2.37% | ▼ −2.53% | $4.17 (+23.37%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $3.38 $3.30 | ▼ −2.37% | ▼ −2.53% | $4.17 (+23.37%) |
|
Mar 4, 2026
14w ago
|
Press Release
| $3.89 $4.16 | ▲ +6.94% | ▲ +7.51% | $4.17 (+7.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access